Search Results
Active Filters
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Jun 15, 2025, 21:25 ET Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025
Oncology (ASCO) Annual Meeting. The subgroup analysis demonstrated that cadonilimab treatment significantly improved progression-free survival (PFS) and overall survival (OS) across different patient subgroups, including: levels of PD-L1 expression, prior treatment with concurrent chemoradiotherapy
More news about: Akeso, Inc.
Jun 15, 2025, 03:15 ET Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
current standard therapies. On average, TCE RRMM patients with EMD have an ORR of less than 40 percent and a median progression-free survival (PFS) of less than 6 months.2 "The investigational combination of TALVEY and TECVAYLI has demonstrated deep, durable responses
More news about: Johnson & Johnson